According to FutureWise analysis, the market for meningococcal vaccine in 2023 is US$ 5.05 billion, and is expected to reach US$ 10.52 billion by 2031 at a CAGR of 9.62%.
Neisseria meningitidis is a type of bacteria that causes the infection known as meningococcal disease. One of the main causes of bacterial meningitis in children between the ages of 2 and 18 in the United States is this invasive bacterium. Meningitis, a serious, sometimes fatal inflammation of the membranes encasing the brain and spinal cord, and/or a potentially fatal blood infection are two possible manifestations of meningococcal illness. Meningococcal illness can result in amputation of limbs, hearing loss, neurological issues, intellectual incapacity, convulsions, and strokes. The meningococcal vaccine is essential for preventing meningococcal illness.
Meningococcal illness is transferred through contact with secretions from the nose and throat (saliva or spit). The illness can spread by kissing, sharing cutlery, drinking from the same cup, sharing a cigarette or lipstick, coughing, and close social contact (such as sharing a home). One of the best ways to stop meningococcal disease is by vaccination. Vaccines against meningococci are used to stop illnesses, including meningitis, meningococcemia, and septicemia, brought on by N. meningitides. Meningococcal illness, particularly meningococcal meningitis, is extremely contagious among individuals. Meningococcal serogroups A, B, C, Y, and W-135 are the most common ones causing the infection out of those found thus far. Meningococcal meningitis is becoming more common, which is a public health concern. Numerous meningococcal infection treatments are available worldwide, yet the illness still claims many lives.
FutureWise Market Research has published a report that provides an insightful analysis of meningococcal vaccine market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the meningococcal vaccine market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.